NCT02703623 trial: what clinicians have said so far
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- NCT02703623 ↗
- Active, not recruiting
- M.D. Anderson Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT02703623 (apalutamide plus abiraterone; ipilimumab plus apalutamide plus abiraterone in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02703623 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Abiraterone Acetate; Apalutamide; Cabazitaxel; Carboplatin; Ipilimumab; Laboratory Biomarker Analysis; Prednisone
- Arms
- Arm 2A (abiraterone acetate, prednisone, apalutamide) · Experimental
- Arm 2B (abiraterone acetate, prednisone, ARN-509, ipilimumab) · Experimental
- Arm 3(abiraterone, prednisone, ARN509,cabazitaxel,carboplatin) · Active comparator
- Enrollment
- 196
- Primary outcomes
- Overall survival (OS)
- Incidence of adverse events as measured by the method of Thall et al
- Androgen receptor (AR) response marker signature
- Allocation serum marker decline
- Sponsor
- M.D. Anderson Cancer Center with National Cancer Institute (NCI)
- Start
- May 18, 2016
- Primary completion
- Mar 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT02703623 · updated Sep 14, 2026